Kyntra Bio, Inc.
KYNB
$7.94
-$0.10-1.22%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 257.49% | -427.61% | -179.08% | 1,274.41% | 51.09% |
| Total Depreciation and Amortization | -97.29% | -97.86% | -97.73% | -74.02% | -71.70% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -1,422.22% | -69.63% | 171.11% | -479.48% | -68.99% |
| Change in Net Operating Assets | -20.84% | 104.78% | 89.87% | -4,925.99% | 154.85% |
| Cash from Operations | -131.47% | -610.74% | 39.84% | 77.95% | 131.81% |
| Capital Expenditure | -- | -- | 100.00% | 89.02% | 7.14% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -3,605.61% | -- | -- |
| Cash from Investing | 136,046.15% | 18,962.50% | -3,101.28% | 11,444.37% | -100.02% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -50.00% | -503,350.00% | 137.50% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | 58.33% | 81.08% | 42.86% | 89.19% | 84.21% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 44.44% | 92.05% | -380.00% | -67,551.18% | -128.13% |
| Foreign Exchange rate Adjustments | -103.06% | -99.93% | 43.68% | 35.71% | -61.95% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 0.04% | -370.39% | -143.20% | 80.78% | -61.00% |